Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease.
about
Promising oncolytic agents for metastatic breast cancer treatmentOncolytic virus therapy for glioblastoma multiforme: concepts and candidatesVesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerGeneration of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vectorEvaluating Replication-Defective Vesicular Stomatitis Virus as a Vaccine VehicleUnderstanding and altering cell tropism of vesicular stomatitis virusLDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virusCutting Edge: Innate Immune Augmenting Vesicular Stomatitis Virus Expressing Zika Virus Proteins Confers Protective ImmunityInterleukin-4 Expressed By Neoplastic Cells Provokes an Anti-Metastatic Myeloid Immune Response.Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapyPotential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse modelsAAV's anatomy: roadmap for optimizing vectors for translational successVesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor controlThe interferon-inducible antiviral protein Daxx is not essential for interferon-mediated protection against avian sarcoma virus.Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus.Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumorsInterferon impedes an early step of hepatitis delta virus infection.Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expressionPermissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68VSV-MP gene therapy strategy inhibits tumor growth in nude mice model of human lung adenocarcinoma.Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic virusesUsing virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.High basal expression of interferon-stimulated genes in human bronchial epithelial (BEAS-2B) cells contributes to influenza A virus resistanceSystemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.VSV-tumor selective replication and protein translation.Targeting cancer-initiating cells with oncolytic viruses.Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.Distinct roles for the NF-kappa B RelA subunit during antiviral innate immune responses.Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm.Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.RNA viruses as virotherapy agents.Vesicular stomatitis virus-simian retrovirus type 2 vaccine protects macaques from detectable infection and B-cell destructionDevelopment of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.
P2860
Q26830620-05553048-A3DF-4D06-9D03-D544A4269468Q27007519-4439C298-C12E-48B7-81A6-C3A2BA16C7A7Q27021839-1D477E5D-B140-4E08-A046-872D89FF1860Q27472940-E3B03C0C-ACCE-4195-8996-9B1B31AF05A4Q27473287-A2C8DBBF-64DE-4163-BB66-C91B734C1065Q27687067-6CDD2C65-3774-4D89-A028-37387599471BQ28118448-D1DEF747-658E-4787-B2F3-C9DFF9554413Q29365197-4E3CF5BD-E76F-4BDB-8F0A-F03410F23F03Q30802553-AC4286A2-FC91-40F1-BBD3-F635E0D3A93EQ33551626-8CDD8A15-55EB-4985-9DAA-6E338F4D78A1Q33579385-DA4759DC-3C77-4287-B895-2024AB996DF1Q33620680-87AA8BC0-C322-477D-A38A-E2967ECA936AQ33659389-D279E470-4720-41B5-A075-51C3632FA820Q33713083-A38BFB2F-B09E-4B8E-B0C1-77BAA142D04CQ33724224-EE7AB0A9-507C-4B17-B883-19542917E6A0Q33726203-6AC6712D-0A7C-4A32-851E-7D3BCEBD5CADQ33747762-8F73B676-B1F1-47C1-88DE-BC1A32647DA0Q33815701-2F591395-8768-4D5C-982C-7AD2AF8BD999Q33832148-398B13E8-4268-4D4C-811B-8867095C05C9Q33936327-B354B4DD-A525-4564-B0B6-C42EB220E084Q33979916-C942B462-439B-44BE-A9A8-92434EFB631CQ33999130-7212C230-CD37-43FB-B0F1-A3B91504CA2FQ34051784-93DD49FB-AB66-4D96-BB5D-E4D31141116EQ34066632-65888E13-C434-4FBE-B90E-CBB8F8309A02Q34092661-04C2BCA5-2C87-429C-B0F0-DB811664D270Q34110261-99F98871-7453-4AAC-A13B-1FCA993493A4Q34198856-E29EFDDC-ECFF-41F5-B1AE-261EB71746B9Q34337520-CA25A592-7520-4A33-B690-9CF54CA6A553Q34371450-AD945FE5-D161-4731-B398-1D3174B0DD66Q34432037-D1F56D10-ECEA-4B45-BC9E-97284540A1E1Q34473352-10EB12D0-8E27-4543-B33D-7090A2F78F14Q34651274-9C19056C-50D8-4909-84A1-FF9BC02F250FQ34659011-E95FCD23-8897-4C11-B0F0-F964145B21E1Q34684399-E2A8FCF6-430E-4136-85F4-B491B0BCDA57Q34742996-4079F462-F7F9-40CA-891E-A140B3F74FF8Q34763799-4BA7265D-5C31-4884-9E10-2A1183067704Q34764685-D5267F9D-5AA8-4483-A92C-C165B84EEA40Q35043090-8A394288-5AE6-4D6E-AB1F-6B67BD525BEAQ35077051-2300B73C-4AB5-4930-9EBA-5535BE2CCEDCQ35182301-07FD92A3-7248-45E7-AB82-65EEFD30F3D8
P2860
Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Genetically engineered vesicul ...... reatment of malignant disease.
@ast
Genetically engineered vesicul ...... reatment of malignant disease.
@en
Genetically engineered vesicul ...... reatment of malignant disease.
@nl
type
label
Genetically engineered vesicul ...... reatment of malignant disease.
@ast
Genetically engineered vesicul ...... reatment of malignant disease.
@en
Genetically engineered vesicul ...... reatment of malignant disease.
@nl
prefLabel
Genetically engineered vesicul ...... reatment of malignant disease.
@ast
Genetically engineered vesicul ...... reatment of malignant disease.
@en
Genetically engineered vesicul ...... reatment of malignant disease.
@nl
P2093
P2860
P1433
P1476
Genetically engineered vesicul ...... reatment of malignant disease.
@en
P2093
Dubravka Markovic
Glen N Barber
Marilyn Fernandez
Mercedes Porosnicu
P2860
P304
P356
10.1128/JVI.76.2.895-904.2002
P407
P577
2002-01-01T00:00:00Z